Activation of muscarinic acetylcholine receptors via their allosteric binding sites
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
8710935
PubMed Central
PMC38737
DOI
10.1073/pnas.93.16.8705
Knihovny.cz E-resources
- MeSH
- Muscarinic Agonists pharmacology MeSH
- Alcuronium pharmacology MeSH
- Allosteric Regulation MeSH
- Cyclic AMP metabolism MeSH
- Muscarinic Antagonists pharmacology MeSH
- Quinuclidinyl Benzilate pharmacology MeSH
- CHO Cells MeSH
- Inositol Phosphates physiology MeSH
- Cricetinae MeSH
- Periodicity MeSH
- GTP-Binding Proteins physiology MeSH
- Receptors, Muscarinic physiology MeSH
- Recombinant Proteins MeSH
- Signal Transduction MeSH
- Strychnine pharmacology MeSH
- Transfection MeSH
- Gallamine Triethiodide pharmacology MeSH
- Animals MeSH
- Check Tag
- Cricetinae MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, U.S. Gov't, P.H.S. MeSH
- Names of Substances
- Muscarinic Agonists MeSH
- Alcuronium MeSH
- Cyclic AMP MeSH
- Muscarinic Antagonists MeSH
- Quinuclidinyl Benzilate MeSH
- Inositol Phosphates MeSH
- GTP-Binding Proteins MeSH
- Receptors, Muscarinic MeSH
- Recombinant Proteins MeSH
- Strychnine MeSH
- Gallamine Triethiodide MeSH
Ligands that bind to the allosteric-binding sites on muscarinic acetylcholine receptors alter the conformation of the classical-binding sites of these receptors and either diminish or increase their affinity for muscarinic agonists and classical antagonists. It is not known whether the resulting conformational change also affects the interaction between the receptors and the G proteins. We have now found that the muscarinic receptor allosteric modulators alcuronium, gallamine, and strychnine (acting in the absence of an agonist) alter the synthesis of cAMP in Chinese hamster ovary (CHO) cells expressing the M2 or the M4 subtype of muscarinic receptors in the same direction as the agonist carbachol. In addition, most of their effects on the production of inositol phosphates in CHO cells expressing the M1 or the M3 muscarinic receptor subtypes are also similar to (although much weaker than) those of carbachol. The agonist-like effects of the allosteric modulators are not observed in CHO cells that have not been transfected with the gene for any of the subtypes of muscarinic receptors. The effects of alcuronium on the formation of cAMP and inositol phosphates are not prevented by the classical muscarinic antagonist quinuclidinyl benzilate. These observations demonstrate for the first time that the G protein-mediated functional responses of muscarinic receptors can be evoked not only from their classical, but also from their allosteric, binding sites. This represents a new mechanism of receptor activation.
See more in PubMed
J Biol Chem. 1995 Mar 31;270(13):7405-10 PubMed
FEBS Lett. 1995 Apr 24;363(3):261-3 PubMed
Biochem Soc Trans. 1995 Feb;23(1):108-11 PubMed
FASEB J. 1995 May;9(8):619-25 PubMed
Trends Pharmacol Sci. 1995 Mar;16(3):89-97 PubMed
J Biol Chem. 1995 Jun 30;270(26):15485-93 PubMed
Biochem Pharmacol. 1995 Jun 29;50(1):17-26 PubMed
J Pharmacol Exp Ther. 1995 Jul;274(1):134-42 PubMed
J Pharmacol Exp Ther. 1995 Jul;274(1):378-84 PubMed
Eur J Pharmacol. 1995 Apr 28;289(2):311-9 PubMed
Mol Pharmacol. 1995 Aug;48(2):362-78 PubMed
Trends Pharmacol Sci. 1995 Jun;16(6):188-92 PubMed
Trends Pharmacol Sci. 1995 Jun;16(6):205-12 PubMed
Trends Pharmacol Sci. 1995 Jul;16(7):232-8 PubMed
J Pharmacol Exp Ther. 1995 Sep;274(3):1077-83 PubMed
Trends Pharmacol Sci. 1995 Aug;16(8):259-60 PubMed
FEBS Lett. 1995 Dec 18;377(2):275-9 PubMed
Br J Pharmacol. 1976 Nov;58(3):323-31 PubMed
Fed Proc. 1981 Nov;40(13):2723-8 PubMed
Mol Pharmacol. 1983 May;23(3):551-7 PubMed
Mol Pharmacol. 1983 Jul;24(1):15-22 PubMed
Br J Pharmacol. 1987 Oct;92(2):327-32 PubMed
J Pharmacol Exp Ther. 1988 Nov;247(2):596-602 PubMed
Mol Pharmacol. 1989 Apr;35(4):469-76 PubMed
J Pharmacol Exp Ther. 1989 Sep;250(3):944-52 PubMed
Annu Rev Pharmacol Toxicol. 1990;30:633-73 PubMed
Mol Pharmacol. 1990 Nov;38(5):674-80 PubMed
Biochem Pharmacol. 1991 Jul 5;42(2):199-205 PubMed
Mol Pharmacol. 1991 Aug;40(2):242-7 PubMed
Biochem Pharmacol. 1991 Oct 24;42(10):1927-32 PubMed
Eur J Pharmacol. 1992 Mar 12;225(3):245-52 PubMed
Biochemistry. 1992 Nov 3;31(43):10634-42 PubMed
Mol Pharmacol. 1992 Oct;42(4):638-41 PubMed
Naunyn Schmiedebergs Arch Pharmacol. 1992 Oct;346(4):383-90 PubMed
J Pharmacol Exp Ther. 1993 Jul;266(1):237-43 PubMed
J Physiol. 1993 Feb;461:743-65 PubMed
Pharmacol Ther. 1993 Jun;58(3):319-79 PubMed
Biochemistry. 1994 Feb 1;33(4):943-51 PubMed
J Biol Chem. 1994 Apr 1;269(13):9767-73 PubMed
Mol Pharmacol. 1994 Mar;45(3):517-23 PubMed
Mol Pharmacol. 1994 Apr;45(4):709-17 PubMed
Mol Pharmacol. 1994 May;45(5):983-90 PubMed
J Neurochem. 1994 Nov;63(5):1932-40 PubMed
Mol Pharmacol. 1994 Oct;46(4):685-92 PubMed
Methods Enzymol. 1994;238:31-56 PubMed
Mol Pharmacol. 1995 Jan;47(1):88-98 PubMed
Fusion with Promiscuous Gα16 Subunit Reveals Signaling Bias at Muscarinic Receptors
The operational model of allosteric modulation of pharmacological agonism
Novel M2 -selective, Gi -biased agonists of muscarinic acetylcholine receptors
Current Advances in Allosteric Modulation of Muscarinic Receptors
Subtype differences in pre-coupling of muscarinic acetylcholine receptors
Allosteric Modulation of Muscarinic Acetylcholine Receptors
Divergence of allosteric effects of rapacuronium on binding and function of muscarinic receptors